Indian CRO GVK Biosciences has spent the last year transitioning from a discovery-focused contractor to a full-service developer, now launching a dedicated clinical research unit to reach drugmakers around the world.
Sales of products for the production animal category in emerging markets were up significantly for French drugmaker Virbac in the first half. It was helped in South America by the integration of Uruguay-based Santa Elena, which it bought last year, but it was not enough to overcome difficult foreign exchange rates and weak sales in the U.S. after having to recall 34 lots of its Iverhart Plus chewable heartworm medicine last year.
CRO Theorem Clinical Research has inked a deal with India's Excel Life Sciences to broaden its footprint in the country, expanding its access to clinical trial sites and bolstering its patient-recruitment capabilities.
GlaxoSmithKline's bribery woes in China apparently go back a bit further than the $489 million scandal that broke last summer. The U.K. company has acknowledged that it fired about 30 staffers in its China vaccines business in 2001 after turning up evidence of corruption.
As polio flare-ups in central Asia, the Middle East and Central Africa continue, a new study suggests that an extra dose of the inactivated polio vaccine could further protect children under 5 years old in high-risk countries.
The pharma sector in India is reeling after the National Pharmaceutical Pricing Authority said it's capping prices on about 100 drugs to treat diabetes and heart disease. And the company that could suffer most isn't India-based.
While geopolitical instability in Eastern Europe would appear to make Russia a risky bet, the size of the market and incoming targets on drug production mean the likes of Abbott Laboratories are still investing. For companies unwilling or unable to strike deals like Abbott's $495 million buyout of Veropharm, a new option is tipped to emerge: CMOs.
In the weeks since Narendra Modi won the Indian election, drugmakers and other manufacturers have looked expectantly to the new government's first budget. Now, with the budget nearing, manufacturers have opened up about what they want and politicians from the United Kingdom have flown in to unveil Cipla's £100 million ($172 million) investment in the former colonial power.
Pfizer has a manufacturing plant underway in Saudi Arabia that is slated to be operating next year. But the drugmaker has just struck a deal that will give it access to additional capacity, as well as products, in that country.
Parexel International is looking to broaden its presence in the Middle East and North Africa, snapping up Turkish CRO Atlas Medical Services.